Maxwell Biomedical Completes Acquisition Of Cardialen'S Assets
12/14/22, 2:09 PM
Maxwell Biomedical announced today that it has completed the acquisition of Cardialen's assets. Cardialen, a Minneapolis, MN based company developed MultiPulseTM Therapy (MPTTM), a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardia (VT). The Cardialen technology compliments Maxwell's proprietary Spatial ResynchronizationTM Therapy (SRTMT), both of which are intended to provide safe, effective, pain-free, device-based alternatives for the long-term treatment of AFib.